Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 176 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lyrica Clear all

Conditions: Postherpetic Neuralgia
Interventions: ADL5747, Placebo, Pregabalin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Opiate Withdrawal Syndrome, Opioid Use
Interventions: LFX/PGB, LFX/PLA-PGB; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: PTSD, Alcohol Use Disorder
Interventions: Pregabalin plus BBCET, Placebo plus BBCET; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Restless Legs Syndrome
Interventions: Pregabalin (Lyrica), Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Fibromyalgia, Painful Diabetic Peripheral Neuropathy
Interventions: prior authorization, no prior authorization; Other
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 17
States / cities: Beverly Hills, California • Lomita, California • Orange, California + 14 more

Conditions: Peripheral Neuropathy, HIV Infections
Interventions: pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more

Conditions: Phantom Pain
Interventions: Pregabalin, Ketamine, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Post-operative Pain
Interventions: lyrica; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Abuse Potential
Interventions: Pregabalin 300mg, pregabalin 450 mg, Pregabalin 300 mg with oxycodone 20 mg, pregabalin 450 mg with oxycodone 20 mg, oxycodone 20 mg, Placebo; Drug
Lead sponsor: Viatris Specialty LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Gulf War Illness
Interventions: Duloxetine, Pregabalin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 44 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Temple, Texas • Waco, Texas

Conditions: Painful Diabetic Neuropathy (PDN), Peripheral Neuropathy With Type 2 Diabetes, Vegan Diet
Interventions: Diet, Medical management; Other
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Hendersonville, North Carolina

Conditions: Anesthesia, Opioid Use
Interventions: Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol; Behavioral · Other · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Dental Pain
Interventions: Pre-Op pregabalin, Pre-Op Placebo 1, Post-Op pregabalin, Post-Op Placebo 1, Post-Op Placebo 2, Post-Op acetaminophen; Drug
Lead sponsor: Nevakar, Inc.; Industry
Eligibility: 17 Years to 55 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Post-Herpetic Neuralgia
Interventions: pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 11 more

Conditions: HIV Infections, Peripheral Neuropathy
Interventions: pregabalin, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more

Conditions: Fibromyalgia
Interventions: pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 72
States / cities: Little Rock, Arkansas • Fresno, California • La Jolla, California + 69 more

Conditions: Irritable Bowel Syndrome
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Pain
Interventions: Not listed
Lead sponsor: Asokumar Buvanendran; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Memantine XR-pregabalin combination therapy; Drug
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Healthy
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 222 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 13
States / cities: Mobile, Alabama • Phoenix, Arizona • Tarzana, California + 9 more

Conditions: Painful Diabetic Peripheral Neuropathy (PDPN)
Interventions: ASP3662, pregabalin, ASP3662 placebo, pregabalin placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 37
States / cities: Anniston, Alabama • Phoenix, Arizona • Fresno, California + 33 more

Conditions: Fibromyalgia
Interventions: pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 89
States / cities: Little Rock, Arkansas • Fresno, California • La Jolla, California + 76 more

Conditions: Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
Interventions: Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 15
States / cities: Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more

Conditions: Alcohol Use Disorder
Interventions: Pregabalin, Placebo; Drug · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD

Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome

Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy

Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain

Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica

Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users

Research Examining Gulf War Illness in Our Nations Service Members

The Treatment of Painful Diabetic Neuropathy With Diet

PROUD Study - Preventing Opioid Use Disorders

Dental Pain Study of Analgesics in Patients Undergoing Molar Removal

Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy

A Safety Study Of Pregabalin In Fibromyalgia

Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome

Use of Driving Tests to Evaluate Patient Performance on Oral Opioids

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

A Controlled Pregabalin Trial In Fibromyalgia

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

Pregabalin Trial for the Treatment of Alcohol Use Disorder